title: Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer.
abstract: Chemotherapy with mitomycin C, ifosfamide and cisplatin (MIC) is reported to produce responses of 56% and 69% in inoperable non-small-cell lung cancer (NSCLC). We evaluated the regimen in 45 similar patients who received up to six courses of 6 mg/m2 mitomycin C, 3 g/m2 ifosfamide, and 50 mg/m2 cisplatin every 3 weeks. In all, 18 patients had limited disease (LD) and 27 had extensive disease (ED). A total of 18 patients responded (40%), 9/18 with LD and 9/27 with ED; there were 4 complete responders. The median duration of response was 25 weeks, and median survival was 32 weeks (range, 2-96 weeks). Toxicity was moderate. Nausea and vomiting were controlled with i.v. dexamethasone and high-dose metoclopramide. Other toxicities included myelosuppression and alopecia. This study confirms that MIC is one of the most active regimens for treatment of NSCLC, with acceptable toxicity.
authors.affiliation: Brompton Hospital, London, UK.
authors.forename: D C
authors.initials: DC
authors.lastname: Currie
authors.forename: D W
authors.initials: DW
authors.lastname: Miles
authors.forename: J S
authors.initials: JS
authors.lastname: Drake
authors.forename: R
authors.initials: R
authors.lastname: Rudd
authors.forename: S G
authors.initials: SG
authors.lastname: Spiro
authors.forename: H M
authors.initials: HM
authors.lastname: Earl
authors.forename: P G
authors.initials: PG
authors.lastname: Harper
authors.forename: J S
authors.initials: JS
authors.lastname: Tobias
authors.forename: R L
authors.initials: RL
authors.lastname: Souhami
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D002945:Cisplatin; D007069:Ifosfamide